Orchid Pharma has entered into an exclusive licensing and supply agreement with Pharmasyntez JSC to commercialize Exblifep (cefepime/enmetazobactam) in Russia. The partnership represents a potential opportunity of approximately USD 178 million over the first 10 years, reflecting the scale of unmet clinical need and significant hospital procurement volumes in the Russian market. Pharmasyntez will hold exclusive rights to register and commercialize the product, while Orchid Pharma will supply the finished dosage form, subject to regulatory approval by the Ministry of Health of the Russian Federation.

Exblifep is a carbapenem-sparing antibiotic designed to treat complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens. The product is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals and is included in IDSA and EUCAST treatment guidelines.

Partnership Details

The agreement leverages Pharmasyntez's deep reach into the Russian hospital procurement system. The company operates eight manufacturing facilities across Russia with annual production exceeding 100 million packages. Its portfolio includes over 320 products, with over 77% listed on Russia's List of Vital and Essential Drugs. The key terms of the agreement are outlined below:

Strategic Significance

Manish Dhanuka, Managing Director of Orchid Pharma, stated that the partnership marks an important step in making Exblifep available to patients in Russia. He emphasized that Pharmasyntez's reach ensures the medicine reaches clinicians and patients who need it. Natalia Malykh, Vice President of Business Development at Pharmasyntez group, highlighted that antimicrobial resistance is a significant challenge and that this agreement enables Russian patients to gain access to modern antibacterial therapy.

Orchid Pharma is a fully vertically integrated pharmaceutical company focused on complex injectable antibiotics. It operates globally approved manufacturing facilities compliant with USFDA and EU-GMP standards. Sathguru Management Consultants acted as the exclusive advisor to Orchid Pharma on the transaction.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE191A01027/193bec65464647b1.pdf

Orchid Pharma has estimated the global sales potential for its novel antibiotic combination, Enmetazobactam-Cefepime, at $1 billion to $2 billion. The company is reportedly nearing a licensing agreement in the United States, with talks described as being in an advanced stage.

Key Highlights of the Enmetazobactam-Cefepime Opportunity

The following table summarizes the key details surrounding Orchid Pharma's antibiotic commercialization initiative:

U.S. Licensing Deal in Advanced Stage

Orchid Pharma is closing in on a licensing deal for the novel antibiotic in the United States, with negotiations reported to be at an advanced stage. The U.S. market represents a critical geography for the commercialization of Enmetazobactam-Cefepime, given its significant healthcare expenditure and demand for novel antibiotics targeting drug-resistant infections. The progression of these licensing discussions underscores the company's strategic focus on expanding the global reach of this antibiotic combination.